HOLX Hologic Inc

-- UGAP joins UNICANCER and AP-HP in awarding public tenders specifying Hologic mammography solutions for hospitals in France

BEDFORD, Massachusetts, Nov. 12, 2014 /PRNewswire/ -- Hologic, Inc. (NASDAQ: HOLX), today announced that Stephanix, Hologic's exclusive distribution partner in France, was awarded the public tender to supply advanced mammography solutions to the l'Union des Groupements d'Achats Publics (UGAP), the largest hospital purchasing group in France. The tender gives UGAP members access to open configurations of Hologic Selenia Dimensions 2D and 3D mammography systems and biopsy solutions without the need for additional tender publications. This is the third in a series of French public tenders awarded to Stephanix for Hologic mammography solutions over the past twelve months, accounting for the three largest tenders that exist in France.

Other tenders awarded to Stephanix for Hologic's mammography equipment include UNICANCER, a group of twenty cancer centers located throughout France and Assistance Publique Hôpitaux de Paris (AP-HP), a consortium of 37 hospitals united in 12 hospital groups.

"It is very gratifying to be awarded tenders by UGAP, UNICANCER and AP-HP for Hologic's leading-edge mammography platform," said Claus Egstrand, Hologic's Group President, International. "These groups represent a significant portion of the healthcare facilities in France, providing an exciting opportunity for Hologic to establish long-term relationships with partners interested in moving the science of breast imaging forward. We look forward to working with these institutions to provide the foundation for a seamless transition to our acclaimed 3D mammography technology."

Stephanix, one of the leading French manufacturers of x-ray equipment and Hologic's strategic distribution partner in France, will play a key role in interacting with members of UGAP, UNICANCER and AP-HP to facilitate purchases under these tenders. "This is a significant milestone for Hologic in France. The Selenia Dimensions system met or exceeded the rigorous technical specifications of each of these tenders. In addition, the clinical evidence supporting the efficacy of Hologic 3D mammography helped to position this as the technology platform of the future," said Jean-Michel Artonne, General Manager, Stephanix.

About Hologic Advanced Mammography Solutions:

The Hologic Selenia Dimensions platform was specifically designed to support both conventional 2D and 3D mammography, in addition to advanced applications including low-dose 3D mammography using C-View software, 3D-guided biopsy and contrast enhanced mammography. Large scale clinical trials have demonstrated that Hologic 3D mammography technology significantly increases the detection of invasive breast cancers while simultaneously reducing false positives.

About Hologic, Inc.:

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products. The Company's core business units focus on diagnostics, breast health, GYN surgical, and skeletal health. With a unified suite of technologies and a robust research and development program, Hologic is dedicated to The Science of Sure. For more information on Hologic, visit www.hologic.com.

Hologic, C-View, Dimensions, Selenia and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.

Forward-looking Statement Disclaimer:

This Media Release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic 3D and 2D mammography systems. There can be no assurance the systems will achieve the benefits described herein and that such benefits will be replicated in any particular manner with respect to an individual patient as the actual effect of the use of the systems can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the statements presented herein to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such statements are based.